Melan-A (A103) and inhibin expression in ovarian neoplasms.

Department of Pathology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, U.S.A.
Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry (Impact Factor: 2.01). 10/2003; 11(3):244-9. DOI: 10.1097/00129039-200309000-00007
Source: PubMed


A103 is a melanocyte-associated monoclonal antibody that recognizes the Melan-A/MART-1 antigen in melanomas. The Melan-A/MART-1 antigen is also expressed in Leydig cells, adrenal tissue, and steroid-secreting tumors. A103 immunoreactivity in ovarian neoplasms, specifically sex cord stromal tumors (SCSTs), has not been well studied. Inhibin is known to be expressed in SCSTs but is also expressed in some carcinomas and other tumors. We sought to explore the usefulness of both antibodies in the diagnosis of ovarian neoplasms. Using conventional tissue sections and a tissue microarray, we studied the immunoreactivities of 131 ovarian tumors for A103 and inhibin: 30 SCSTs, including fibrothecoma, luteoma, hilus cell tumor, granulosa cell tumor, Sertoli-Leydig cell tumor, and sex cord tumor with annular tubules, and a control group of 96 surface epithelial tumors. A few other rare ovarian tumors including 1 small cell carcinoma, 1 adenocarcinoid tumor, 1 ovarian tumor of probable wolffian origin, 1 Krukenberg tumor, and 1 desmoplastic small round cell tumor were also studied. Inhibin staining was generally strong and diffuse in the majority of SCSTs (83%) and at least focally positive in the small cell carcinoma, ovarian tumor of probable wolffian origin, Krukenberg tumor, and desmoplastic small round cell tumor. Variable immunoreactivities were also present in 7 of 96 (7.3%) surface epithelial tumors. In comparison, A103 expression was usually weaker and more focal than that of inhibin and was present in a smaller proportion of SCSTs (37%) and negative in all the surface epithelial tumors. A103 was typically positive in the lipid-containing cells (both neoplastic and normal components) of these tumors (fibrothecomas, luteomas, Sertoli-Leydig cell tumors, hilus cell tumors, and granulosa cell tumors), and in some cases, moderate positivity was noted in these cells. Weak A103 positivity was identified in the single case of ovarian tumor of probable wolffian origin. A103 is relatively less sensitive than inhibin for recognizing SCSTs but does not appear to be expressed by ovarian surface epithelial tumors. It is therefore more specific than inhibin for SCSTs and is a useful marker for specifically identifying lipid-containing cells in tumors. Thus, adding A103 to a panel of markers including inhibin may be a valuable adjunct in the differential diagnoses of SCSTs and their distinction from other ovarian neoplasms.

Download full-text


Available from: Rebecca Baergen, Apr 08, 2015
30 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sertoliform endometrioid carcinoma (SEC) of the ovary is an uncommon variant of endometrioid carcinoma of the ovary resembling sex cord-stromal tumor of pure Sertoli and Sertoli-Leydig cell type (SLCT). This entity was first described by Young et al. (1982). Since then only a few cases of this entity have been reported (Roth et al. 1982; Guerrieri et al. 1998; Remadi et al. 1995). SEC occurs in peri- and post menopausal women with an age range of 41–89 years (mean, 60 years). Abdominal enlargement secondary to a unilateral ovarian mass is the most common presentation. Up to 10% cases show bilaterality (Young et al. 1982). The patients very rarely present with androgenic symptoms such as virulization and, to date estrogenic manifestations have been reported in one case in a series of 13 cases (Young et al. 1982). Adequate sampling, a careful search for areas of conventional endometrioid carcinoma and immunohistochemical stains is helpful in the evaluation of SEC from true ovarian sex cord stromal tumors. It is important to recognize this variant of endometrioid carcinoma and especially differentiate it from a sex cord stromal tumor. SEC as it behaves, is a low grade malignancy and displays a good prognosis if confined to the ovary.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Approximately one third of lymphomas arise at an extranodal site (primary extranodal lymphomas), and both primary nodal lymphomas and leukemias not infrequently infiltrate extranodal tissues secondarily during their course. The genitourinary tract is the site of less than 5% of primary extranodal lymphomas [1]. Among these the testis is the most frequent site. Postmortem studies indicate that the genitourinary tract is secondarily involved by lymphoid neoplasms in up to 50% of patients, and such involvement may be clinically apparent in up to 10% of patients [2]. Lymphoid neoplasms are currently classified according to the World Health Organization (WHO) Classification of Tumors of the Hematopoietic and Lymphoid tissues [3]. In this globally accepted classification, devised by an international panel of pathologists, hematologists, and oncologists, lymphomas and leukemias are categorized into discrete entities according to morphological, immunohistological, genetic, and clinical features. Although some lymphomas are defined by their sites of origin, there are no lymphoid neoplasms that arise only in the genitourinary tract. In the clinical setting, the correct identification and then subclassification of lymphoid neoplasms by urologists and urological pathologists is crucial, as many of the entities defined have distinctive clinicopathological features, therapeutic needs, and prognoses, and all require specialist management. Another major determinant of treatment choice and outcome is the stage of lymphoma at presentation. In this regard, lymphomas of the genitourinary tract are, like lymphomas arising elsewhere, staged according to the Ann Arbor staging system.
    12/2004: pages 309-331;
Show more